Category: <span>Aduro Biotech</span>

Category: Aduro Biotech

Aduro Biotech, CRS-207, Dr. Thierry Jahan, FDA, Immunotherapy drug, malignant pleural mesothelioma, mesothelioma, mesothelioma clinical trial, Mesothelioma News, Orphan Drug Designation, U.S. Food and Drug Administration

Promising Clinical Trial Results For A Mesothelioma Immunotherapy Drug

 

Promising results from another phase of a clinical trial for an immunotherapy drug for mesothelioma, CRS-207, have been released.